cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Vera Therapeutics Inc
4 own
2 watching
Current Price
$38.69
$-1.26
(-3.15%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
708.93M
52-Week High
52-Week High
50.78000
52-Week Low
52-Week Low
6.07000
Average Volume
Average Volume
0.85M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization708.93M
icon52-Week High50.78000
icon52-Week Low6.07000
iconAverage Volume0.85M
iconDividend Yield--
iconP/E Ratio--
What does the Vera Therapeutics Inc do?
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Read More
How much money does Vera Therapeutics Inc make?
News & Events about Vera Therapeutics Inc.
Stock Options Channel
10 months ago
Investors considering a purchase of Vera Therapeutics Inc (VERA) stock, but tentative about paying the going market price of 17.25/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the December ...
Benzinga
10 months ago
On Saturday,Vera Therapeutics Inc(NASDAQ: VERA) announced that the Phase 2b ORIGIN trial of atacicept for the treatment of IgA nephropathy (IgAN) met its primary and key secondary endpoints, with statistically significant and clinically meaningful reductions in proteinuria and read more...
PR Newswire
10 months ago
Thinking about buying stock in iCAD, Voxeljet, NeoVolta, Vera Therapeutics, or Nio Inc? Thinking about buying stock in iCAD, Voxeljet, NeoVolta, Vera Therapeutics, or Nio Inc? PR Newswire NEW YORK, June 20, 2023 NEW YORK, June 20, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch...
Globe Newswire
10 months ago
Figure 1 UPCR % Change With Atacicept 150 mg at Week 36 Figure 2 eGFR % Change With Atacicept 150 mg Through Week 36 New data at week 36 shows atacicept 150 mg resulted in a delta of 43% versus placebo in mean proteinuria reduction in per-protocol analysis and demonstrated statistically ...
PR Newswire
10 months ago
Thinking about trading options or stock in Xpeng Inc, Apple, NVIDIA, Chinook Therapeutics, or Vera Therapeutics? Thinking about trading options or stock in Xpeng Inc, Apple, NVIDIA, Chinook Therapeutics, or Vera Therapeutics? PR Newswire NEW YORK, June 12, 2023 NEW YORK, June 12, 2023 /PRNewswire...
Frequently Asked Questions
Frequently Asked Questions
What is Vera Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Vera Therapeutics Inc shares?
plus_minus_icon
How can I buy Vera Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Vera Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Vera Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Vera Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Vera Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Vera Therapeutics Inc?
plus_minus_icon
What percentage is Vera Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Vera Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$38.69
$-1.26
(-3.15%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00